Bayer (BAYRY) Upgraded at Zacks Investment Research

Bayer (OTCMKTS:BAYRY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Bayer’s earnings beat estimates and revenues declined year over year in the fourth quarter of 2017.  During the fourth quarter of 2017, the Crop Science business reported declined mainly due to the situation in the Brazilian crop protection business. As part of its strategy to complete the planned acquisition of Monsanto, Bayer inked an agreement to sell its entire Crop Science businesses to BASF. The combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. However, the company is facing generic competition for many of its products including the Yaz franchise (oral contraceptives). The generics of key drugs will negatively impact revenues. Bayer’s dependence on its pharmaceutical segment for growth remains a concern. Bayer’s shares have underperformed the industry in the last six months.”

Separately, ValuEngine lowered shares of Bayer from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd.

Bayer (OTCMKTS BAYRY) traded down $0.67 during trading on Tuesday, reaching $29.66. 383,284 shares of the company’s stock were exchanged, compared to its average volume of 424,168. The firm has a market cap of $99,895.56, a price-to-earnings ratio of 19.87, a PEG ratio of 1.93 and a beta of 1.20. Bayer has a 12 month low of $27.80 and a 12 month high of $35.41. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.01 and a current ratio of 1.51.

Bayer (OTCMKTS:BAYRY) last released its earnings results on Wednesday, February 28th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.11. The company had revenue of $10.12 billion for the quarter. Bayer had a net margin of 10.84% and a return on equity of 22.39%. analysts predict that Bayer will post 2.38 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Bayer (BAYRY) Upgraded at Zacks Investment Research” was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at

About Bayer

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Get a free copy of the Zacks research report on Bayer (BAYRY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with's FREE daily email newsletter.

Leave a Reply